Welcome to ActHIB.com
Success of immunization
The use of conjugate Hib vaccines represents one of the most dramatic immunization success stories. In the early 1980s, an estimated 20,000 Hib cases occurred each year in the United States, mostly among children under 5 years of age. With the introduction of Hib vaccine in 1987, the number of Hib cases began to drop and has declined by more than 99% compared with the pre-vaccine era.1
Learn more about ActHIB vaccine now 
Haemophilus influenzae type b (Hib) invasive disease among children (less than 5 years old), United States, 1991-2004. 1-4
- Despite the dramatic decline of Hib disease in the United States compared with the pre-vaccine era, Centers for Disease Control and Prevention (CDC) surveillance activities show that Hib disease continues to exist within the United States4-6
- The continued occurrence of Hib disease clearly demonstrates that H influenzae, a resilient and persistent respiratory pathogen, continues to circulate among the general US population6
- Therefore, continued vigilance and high Hib vaccination coverage rates are essential for effective disease prevention
Learn more about Hib disease now
Consumers are encouraged to speak to their health-care providers about immunization with ActHIB vaccine. The information provided on this site is not intended to substitute for the advice of health-care professionals.
References: 1. Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book. 9th ed. Washington, DC: Public Health Foundation; 2006:111-123. 2. CDC. Summary of notifiable diseases-United States, 2002. MMWR. 2004;51:70,72. 3. CDC. Notice to readers: final 2003 reports of notifiable diseases. MMWR. 2004;53:687, 691. 4. CDC.Summary of notifiable diseases - United States, 2004. MMWR. 2006;53:23. 5. CDC. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. MMWR. 2002;51:234-237. 6. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? J Pediatr. 2003:143(suppl):163-185.
Indication
ActHIB vaccine is indicated for the active immunization of infants and children 2 through 18 months of age for prevention of invasive Haemophilus influenzae type b disease.
Safety Information
The most common local and systemic adverse reactions to ActHIB vaccine include injection site erythema, swelling, and tenderness; fever irritability, drowsiness, and anorexia. Other adverse reactions may occur. ActHIB vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Vaccination with ActHIB vaccine may not protect all individuals.
Before administering ActHIB vaccine, please see accompanying full Prescribing Information.
|
